C. Hill, Epidémiologie du cancer du sein, 2007.
DOI : 10.1016/j.lpm.2014.01.014

. Inca, Institut national du cancer) Recommandations professionnelles. Cancer du sein infiltrant non métastatique ? Questions d'actualité

M. Héry, Natural history of node-negative breast cancer: are conventional prognostic factors predictors of time to relapse?, The Breast, vol.11, issue.5, 2002.
DOI : 10.1054/brst.2002.0462

E. Luporsi and J. Bellocq, uPA/PAI-1, Oncotype DX, Mammaprint. Valeurs pronostique et prédictive pour une utilité clinique dans la prise en charge du cancer du sein, Bull Cancer, 2015.
DOI : 10.1007/s10269-014-2379-x

URL : http://dx.doi.org/10.1016/j.bulcan.2015.05.003

J. Gerdes, Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67, J Imunol, 1984.

M. Ellis, Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics, JNCI Journal of the National Cancer Institute, vol.100, issue.19, 2008.
DOI : 10.1093/jnci/djn309

G. Viale, Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer, JNCI Journal of the National Cancer Institute, vol.100, issue.3, 2008.
DOI : 10.1093/jnci/djm289

E. Luporsi, Ki67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review, Breast Cancer Res Treat, 2012.

D. Azambuja and E. , Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12???155 patients, British Journal of Cancer, vol.27, issue.10, 2007.
DOI : 10.1002/1097-0142(19910115)67:2<421::AID-CNCR2820670217>3.0.CO;2-Q

R. Stuart-harris, Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients, The Breast, vol.17, issue.4, 2008.
DOI : 10.1016/j.breast.2008.02.002

R. Yerushalmi, Ki67 in breast cancer: prognostic and predictive potential, The Lancet Oncology, vol.11, issue.2, 2010.
DOI : 10.1016/S1470-2045(09)70262-1

A. Goldhirsch, Strategies for subtypes ? dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, Ann Oncol, 2011.

R. Simon, Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers, JNCI Journal of the National Cancer Institute, vol.101, issue.21, 2009.
DOI : 10.1093/jnci/djp335

G. Viale, Prognostic and predictive value of centrally reviewed Ki-67 labelling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole

F. Penault-llorca, Changes and Predictive and Prognostic Value of the Mitotic Index, Ki-67, Cyclin D1, and Cyclo-oxygenase-2 in 710 Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, The Oncologist, vol.13, issue.12, 2008.
DOI : 10.1634/theoncologist.2008-0073

W. Jonat, Is the Ki-67 labelling index ready for clinical use? Ann Oncol, 2011.

. Réseau-de-cancérologie-de-la-région-centre, Référentiels de prise en charge des cancers du sein

. Réseau-de-cancérologie-d-'aquitaine, Référentiel régional de prise en charge des cancers du sein non métastatiques. Mise à jour : septembre

R. Basse-normandie, Référentiel du cancer du sein (Recommandations pour la Pratique Clinique)

L. Harris, American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer, Journal of Clinical Oncology, vol.25, issue.33, 2007.
DOI : 10.1200/JCO.2007.14.2364

F. Penault-llorca, Adjuvant breast cancer: which clinical and pathological characteristics en 2007? Bull Cancer, 2010.

F. Penault-lorca, Cancers infiltrants de bon pronostic : trop ou pas assez ? Mieux faire que les facteurs histopronostiques classiques TN et grade histopronostique : biochimie ou immunohistochimie ?, p.33, 2011.

S. Teutsch, The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group, Genet Med, 2009.

M. Cheang, Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer, JNCI Journal of the National Cancer Institute, vol.101, issue.10, 2009.
DOI : 10.1093/jnci/djp082

C. Liedtke, AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014, Breast Care, vol.9, issue.3, 2014.
DOI : 10.1159/000363591

M. Aleskandarany and . Mib1, Ki67 labelling index can classify grade 2 breast cancers into two clinically distinct subgroups Breast Cancer Res Treat 2010. 39. Mengel M. Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial, J Pathol, 2002.
DOI : 10.1007/s10549-010-1028-3

M. Polley, An International Ki67 Reproducibility Study, JNCI Journal of the National Cancer Institute, vol.105, issue.24, 2013.
DOI : 10.1093/jnci/djt306

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888090

Z. Varga, How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists, PLoS ONE, vol.12, issue.5, 2012.
DOI : 10.1371/journal.pone.0037379.t003

E. Gudlaugsson, Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer, Histopathology, vol.324, issue.6, 2012.
DOI : 10.1111/j.1365-2559.2012.04329.x

M. Dowsett, Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group, JNCI Journal of the National Cancer Institute, vol.103, issue.22, 2011.
DOI : 10.1093/jnci/djr393

G. Recommandations, Est pour la pratique clinique et outil de l'Association française d'Assurance Qualité en anatomie pathologique (afAQap) pour la détermination de l'index Ki-67 en cas de marquage tumoral immunohistochimique hétérogène par plages, 2014.

T. Novocastra and . Anticorps-monoclonal-liquide-de-souris, Ki67 Antigen Référence du Produit : NCL-L-Ki67-MM1. Notice d'utilisation